Doubts Over DBV's Future As US FDA Rejects Peanut Allergy Patch
Development Of Viaskin Peanut Not Smooth
The French company's hopes of joining Aimmune's Palforzia on the peanut allergy market soon have been shattered after US regulators issued a complete response letter to its Viaskin Peanut patch. A lot now depends on how much work DBV will have to do to satisfy the FDA.
